FA
CPRX

Friess Associates’s Catalyst Pharmaceutical CPRX Stock Holding History

Friess Associates’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$2.14M Sell
305,148
-266,792
-47% -$1.96M 3.57% 12
2022
Q1 		$4.74M Buy
+571,940
New +$4.04M 2.53% 7

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Friess Associates's CPRX Position: Q2 2022 in Review

Friess Associates reduced its Catalyst Pharmaceutical (CPRX) stake by 47% in Q2 2022, selling an estimated $1.96M and leaving 305,148 shares worth $2.14M. The position accounts for 3.57% of the portfolio, ranked #12.

Friess Associates first reported a position in CPRX in Q1 2022 and has held it in 2 quarters since. The position peaked at $4.74M in Q1 2022. 189 funds tracked by Wall St. Rank hold CPRX as of Q2 2022.

  • Friess Associates held 305,148 shares of Catalyst Pharmaceutical worth $2.14M as of Q2 2022.
  • Friess Associates sold 266,792 Catalyst Pharmaceutical shares in Q2 2022, an estimated $1.96M.
  • Catalyst Pharmaceutical made up 3.57% of Friess Associates's portfolio in Q2 2022, its #12 holding.
  • Friess Associates first reported a position in Catalyst Pharmaceutical in Q1 2022 and has held it in 2 quarters since.
  • Friess Associates's Catalyst Pharmaceutical position peaked at $4.74M in Q1 2022.
  • 189 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2022.

Based on Friess Associates's 13F filing for Q2 2022, filed 15 Aug 2022.